PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of f1000medLatest ContentReportsReportsReports
 
F1000 Med Rep. 2009; 1: 21.
Published online 2009 March 17. doi:  10.3410/M1-21
PMCID: PMC2920712

Biomarkers in predicting mortality and treatment in hemodialysis patients

Abstract

Circulating natriuretic peptides are useful biomarkers of left ventricular dysfunction and heart failure in the general population. Cardiac troponin T (cTnT) is also considered a sensitive marker of myocardial injury. However, the fact that levels of circulating natriuretic peptides and cTnT are almost invariably increased in end-stage renal disease patients has been considered a major limitation for their use as diagnostic or prognostic tools in this population. We provide an updated review on the role of natriuretic peptides and cTnT as biomarkers in predicting outcome and treatment in the hemodialysis population.

Introduction and context

Cardiovascular disease is the leading cause of mortality in patients with end-stage renal disease (ESRD) and is partly attributed to the very high prevalence of left ventricular (LV) abnormalities, including LV hypertrophy, systolic dysfunction and congestive heart failure. The Kidney Disease Outcome Quality Initiative (KDOQI) guidelines have, therefore, made the recommendation that echocardiography be performed at initiation of dialysis in all ESRD patients and every 3 years thereafter [1]. However, echocardiography services are very often stretched in hospitals and not routinely performed in most dialysis centers. Therefore, circulating biomarkers that identify patients with subclinical heart disease or diseased myocardium may have a potentially important clinical value in allowing early detection, intervention and possibly ongoing surveillance of high-risk patients. In recent years, the natriuretic peptides have emerged as promising cardiac biomarkers in this aspect.

The B-type, or brain natriuretic peptide (BNP) is a 32 amino acid peptide hormone predominantly released from the ventricles in response to LV volume expansion and pressure overload [2-4] and has a circulating half-life of 23 minutes. N-terminal pro-BNP (NT-pro-BNP) is a 76 amino acid peptide hormone also cleaved from the prohormone; it is biologically inactive but has a much longer half-life (120 minutes). BNP levels are well known to correlate with LV filling pressures and are elevated in patients with LV dysfunction [2,5]. Both BNP and NT-pro-BNP levels increased in proportion to the severity of heart failure as assessed using the New York Heart Association classification in the general population [6,7]. In patients without chronic kidney disease (CKD), BNP and NT-pro-BNP testing are found to be most useful in ruling out the diagnosis of heart failure in those presenting with dyspnoea [8-11]. The value of BNP or NT-pro-BNP testing in predicting prognosis has also been established in the general population [12].

In stage 5 CKD patients receiving hemodialysis or peritoneal dialysis, BNP and NT-pro-BNP are almost invariably increased compared to normal cutoffs [13-19]. These elevations were partly attributed to decreased renal clearance, chronic volume overload as well as to the very high prevalence of cardiac abnormalities [13-19]. NT-pro-BNP has been shown to be inversely related to residual renal function in both hemodialysis and peritoneal dialysis patients [15,16]. A study in the non-ESRD population also confirmed renal dysfunction as a potential cause of markedly elevated BNP and NT-pro-BNP in the absence of LV systolic dysfunction [20]. Thus, in dialysis patients, BNP and NT-pro-BNP levels have to be interpreted in light of the presence or absence of residual renal function. BNP and NT-pro-BNP have been shown to be strongly associated with LV hypertrophy and dilation, and systolic dysfunction, in both hemodialysis and peritoneal dialysis patients [14-19]. NT-pro-BNP was also associated with coronary artery disease in non-dialysis CKD patients [21].

On the other hand, cardiac troponin T (cTnT) is a sensitive marker of myocardial injury and is the current gold standard test for diagnosis of acute myocardial necrosis in the general population. However, levels of cTnT are frequently elevated in the absence of acute coronary syndrome among patients with varying degrees of kidney disease [22-28]. Using the 99th percentile cutoff of 0.1 μg/L, the prevalence of cTnT elevation was reported to range from 30 to 85% in ESRD patients [22-27]. This led to the initial suggestion that cTnT may have limited diagnostic or prognostic value in patients with CKD. In the GUSTO IV (Global Use of Strategies to Open Occluded Coronary Arteries IV) trial, elevated cTnT was strongly predictive of poor short-term prognosis irrespective of creatinine clearance in patients with suspected acute coronary syndrome [29]. Notably, cTnT elevation had even greater prognostic importance among patients with mild to moderate degrees of kidney disease, clearly confirming the specificity of cTnT as a marker of myocardial injury among patients with kidney disease.

There is robust evidence that cTnT is a powerful prognostic marker in ESRD patients. One of the earliest and largest studies, by Apple et al. [26], showed that an elevated cTnT>99th percentile cutoff was predictive of both short-term and long-term mortality in hemodialysis patients. Numerous other studies have demonstrated similar prognostic importance of cTnT in hemodialysis patients [22-25,27].

Recent advances

Diagnostic value of BNP or NT-pro-BNP for LV systolic dysfunction in hemodialysis patients

In a recent small study, a serum NT-pro-BNP cutoff ≥7200 ng/L was suggested to be useful in diagnosing LV systolic dysfunction in hemodialysis patients, regardless of the patients' fluid status, with a specificity of 90% and a sensitivity of 79%. Further reducing the cutoff to approximately 5000 ng/L increased the sensitivity in diagnosing LV systolic dysfunction to >90% but reduced the specificity to 80% [30]. This observation was very similar to the earlier Cardiovascular Risk Evaluation Extension (CREED) study, suggesting the potential value of BNP testing in ruling out systolic dysfunction in the dialysis population [14]. However, the best cutoff of BNP or NT-pro-BNP in diagnosing or ruling out systolic dysfunction will need stratification according to residual renal function and will require further confirmation in a larger cohort of the dialysis population. Notably, in patients with LV systolic dysfunction, persistent post-dialytic volume overload was significantly related to serum levels of NT-pro-BNP [30]. A number of other studies reported similar correlations between markers of hypervolemia and high plasma BNP or NT-pro-BNP [31,32]. However, so far there are no convincing data to suggest that BNP or NT-pro-BNP represent useful markers of volume status in hemodialysis patients [16,33].

Prognostic value of baseline BNP and NT-pro-BNP in dialysis patients

BNP and NT-pro-BNP are increasingly recognized to be powerful predictors of mortality and cardiovascular death in the dialysis population. In one of the earliest prospective cohort studies, performed in 399 hemodialysis patients, NT-pro-BNP was associated with 2-year all-cause mortality and, in a smaller study, with 3-year cardiac morbidity and mortality [13]. The CREED study showed that plasma BNP taken on a non-dialysis day was predictive of overall and cardiovascular death in hemodialysis patients [34]. A more recent study by Madsen et al. [16] also showed that both pre- and post-hemodialysis NT-pro-BNP were predictive of 2-year mortality. These data clearly suggested that levels of BNP and NT-pro-BNP had powerful prognostic implications irrespective of whether the measurement was taken before, shortly after or in-between dialysis. One study showed that both pre- and post-dialysis BNP and NT-pro-BNP were strongly correlated [35]. However, given that levels of BNP and NT-pro-BNP were altered by hemodialysis [16,35], it is important to standardize the timing of measurement of BNP or NT-pro-BNP in relation to the dialysis session in hemodialysis patients.

In peritoneal dialysis patients, NT-pro-BNP was predictive of long-term (3 years) all-cause mortality, cardiovascular death and events as well as cardiovascular congestion independent of echocardiographic measures of LV mass and ejection fraction [15]. Post hoc analysis from the Adequacy of Dialysis in Mexico (ADEMEX) study also showed a similar finding that the baseline NT-pro-BNP level was independently predictive of overall survival and cardiovascular death in peritoneal dialysis patients, irrespective of treatment arm [36].

A recent study compared the prognostic value of NT-pro-BNP and cTnT in hemodialysis patients and showed that NT-pro-BNP was strongly correlated with LV systolic dysfunction and was indeed more strongly associated with mortality than cTnT [17]. However, the combination of cTnT and NT-pro-BNP did not improve the association with all-cause and cardiovascular mortality compared to NT-pro-BNP alone. NT-pro-BNP was a marker of mortality even after adjusting for LV mass index and midwall fractional shortening. These data suggest that NT-pro-BNP may be a more powerful prognostic marker compared to cTnT.

Role of serial monitoring of NT-pro-BNP for outcome prediction in dialysis patients

More recently, a prospective cohort study performed in 2,990 incident hemodialysis patients reported similar findings; increased NT-pro-BNP level was independently associated with increased risk of mortality at 90 days and 1 year [37]. Furthermore, in a smaller subset of 585 incident hemodialysis patients, repeat measurement of NT-pro-BNP was performed at 3 months. Patients with the greatest increase in NT-pro-BNP after 3 months of dialysis showed a 2.4-fold higher risk of mortality than those with the greatest decrease in NT-pro-BNP. These data for the first time suggested that serial changes in NT-pro-BNP levels also carried important prognostic information, independent of baseline NT-pro-BNP level, and were predictive of subsequent mortality [37].

Notably, in the recent post hoc analysis of the German Diabetes Dialysis Study (4D Study), which evaluated atorvastatin in 1,255 type 2 diabetic ESRD patients on maintenance hemodialysis, it was found that increased NT-pro-BNP over at least a 6-month period was strongly predictive of an increased risk of sudden death, cardiovascular event and mortality. Doubling of NT-pro-BNP was associated with a 46% increase in the risk of death. Furthermore, the increased risk of mortality with rising NT-pro-BNP was independent of baseline NT-pro-BNP and baseline co-morbidity [38].

Prognostic value of cardiac troponin T in dialysis patients

In a recent meta-analysis based on 28 studies published between 1999 and 2004 and including 3,931 patients, cTnT was shown to be a useful risk stratification tool in the ESRD population. The pooled analysis indicated that an elevated cTnT (>0.1 μg/L) is useful in identifying a subgroup of asymptomatic ESRD patients with poor survival and a higher risk of cardiac death [39]. Recently, the Food and Drug Administration has approved the use of cTnT as a biomarker for mortality risk stratification in ESRD patients. Similarly, the use of cTnT for predicting prognosis has also been recommended by the KDOQI [1]. Of note, the NECOSAD (Netherlands Cooperative Study on the Adequacy of Dialysis) showed only limited added predictive power of cTnT over other clinical risk factors in a combined cohort of hemodialysis and peritoneal dialysis patients [40]. This observation was somewhat contrary to our recent finding that cTnT had a significant additional value for prognostication beyond the standard clinical, biochemical, dialysis and echocardiographic measures, including LV mass and ejection fraction in chronic peritoneal dialysis patients [41]. More importantly, our study showed that the prognostic value of cTnT was independent of inflammation, residual renal function, LV hypertrophy and dysfunction, clearly supporting the additional value of measuring cTnT for early identification of high-risk ESRD patients. A recent study also showed that cTnT is a useful biomarker in predicting the development of circulatory congestion in chronic peritoneal dialysis patients [42]. These data suggest that cTnT serves as an important adjunct to echocardiography in identifying peritoneal dialysis patients at risk of circulatory congestion. Whether the findings are also applicable to hemodialysis patients requires further evaluation.

Mechanisms of elevated cTnT in dialysis patients

Elevated cTnT has been linked to LV hypertrophy, LV dilation, diabetes, and impaired systolic and diastolic dysfunction in hemodialysis patients [43-45]. There is evidence that elevated cTnT in asymptomatic ESRD patients reflects subclinical myocardial injury. Ooi et al. [46] showed that elevated cTnT was invariably associated with pathological evidence of old, recent or healing myocardial necrosis or micro-infarction. In another study, cTnT elevation was closely correlated with the severity of angiographic coronary artery disease in chronic hemodialysis patients [47]. cTnT elevation has also been linked to the degree of coronary artery calcification in asymptomatic hemodialysis patients [48]. Even though cTnT was significantly confounded by residual kidney function [41], circulating cTnT in patients with kidney failure was noted to be predominantly the free-intact form, as in patients with acute coronary syndrome [49]. This was important evidence to support that circulating cTnT in ESRD patients is indeed a marker of cardiac pathology. Given that free and bound cTnT are both relatively large molecules of 37 and 77kDa, respectively, elevated cTnT in ESRD patients is unlikely to be the result of decreased renal clearance. Using contrast magnetic resonance imaging, a recent study showed that elevated cTnT cannot be solely attributed to previous subclinical myocardial necrosis or LV hypertrophy [50]. It was speculated that additional myocardial pathologies, such as myocardial fibrosis, may contribute to increased cTnT in ESRD patients and require further evaluation.

Implications for clinical practice

Clinical utility of BNP/NT-pro-BNP in hemodialysis patients

Together, these data suggest that serial monitoring of NT-pro-BNP levels may represent a novel and useful clinical tool in guiding treatment efficacy in the dialysis population and warrant further investigation. Treatment guided by lowering plasma NT-pro-BNP levels has been shown to reduce cardiovascular events and delay time to first cardiovascular event, compared with usual clinically guided treatment in patients with chronic heart failure [51]. A BNP-guided strategy has also been shown to reduce the risk of heart-failure related death or length of hospital stay for heart failure, compared to standard clinical care in the general population [52]. In a recent small prospective study of 21 stable hemodialysis patients with preserved systolic function, changes in LV mass index over 6-month and 12-month periods were closely correlated with changes in NT-pro-BNP levels [53]. All these observations prompt further investigation into the application of serial BNP and NT-pro-BNP monitoring as biomarkers for assessing changes in LV mass index or systolic function in hemodialysis patients. Whether BNP or NT-pro-BNP guided therapy may be useful in monitoring treatment efficacy and improving clinical outcomes of hemodialysis patients needs further prospective evaluation.

Clinical utility of cTnT in hemodialysis patients

How can cTnT testing be applied in daily clinical practice? Given that cTnT is confounded by residual kidney function, we believe a baseline level should first be obtained in all hemodialysis patients in order to distinguish subsequent cTnT elevation due to acute coronary syndrome and/or chronic myocardial injury. The measurement should best be obtained before dialysis because cTnT levels may increase post-dialysis [54]. A baseline level not only allows outcome prediction and identifies high-risk patients, but also forms an important basis to evaluate changes over time. Our recent data suggested that even minimally increased cTnT is associated with an increased risk of mortality and cardiovascular death in peritoneal dialysis patients [41]. This is well in accord with observations in the general population suggesting that a minimally increased cTnT concentration reflects increased cardiovascular risk [55]. According to the recent National Academy of Clinical Biochemistry (NACB) laboratory medicine practice guidelines, measurement of cardiac troponins should also be used to evaluate acute coronary syndrome in ESRD patients [56]. In ESRD patients who present with possible acute coronary syndrome, a dynamic change in cardiac troponins of ≥ 20% after presentation should be used to define acute coronary syndrome. In addition, testing for cardiac troponins may be used as an aid in defining the risk of mortality in ESRD patients. Whether cTnT testing may be a useful screening test for cardiovascular disease in the hemodialysis population warrants further evaluation.

Abbreviations

BNP
brain natriuretic peptide
CKD
chronic kidney disease
CREED
Cardiovascular Risk Evaluation Extension
cTnT
cardiac troponin T
ESRD
end-stage renal disease
KDOQI
Kidney Disease Outcome Quality Initiative
LV
left ventricular
NT-pro-BNP
N-terminal-pro-brain natriuretic peptide

Notes

The electronic version of this article is the complete one and can be found at: http://www.F1000.com/Reports/Medicine/content/1/21

Notes

Competing interests

The author declares that she has no competing interests.

References

1. K/DOQI Workgroup K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(3):16–153. doi: 10.1053/j.ajkd.2005.01.019. [PubMed] [Cross Ref]
2. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195–203. [PubMed]
3. Hosoda K, Nakao K, Mukoyama M, Saito Y, Jougasaki M, Shirakami G, Suga SI, Ogawa Y, Yasue H, Imura H. Expression of brain natriuretic peptide gene in human heart: production in the ventricle. Hypertension. 1991;17:1152–5. [PubMed]
4. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology. 1993;132:1961–70. doi: 10.1210/en.132.5.1961. [PubMed] [Cross Ref]
5. Yamamoto K, Burnett J, Jougasaki M, Nishimura RA, Bailey KR, Saito Y, Nakao K, Redfield MM. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–94. [PubMed]
6. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–7. doi: 10.1056/NEJMoa020233. [PubMed] [Cross Ref]
7. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997;47:287–96. doi: 10.1046/j.1365-2265.1997.2361058.x. [PubMed] [Cross Ref]
8. Battaglia M, Pewsner D, Juni P, Egger M, Bucher HC, Bachmann LM. Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: systematic review of test accuracy studies. Arch Intern Med. 2006;166:1073–80. doi: 10.1001/archinte.166.10.1073. [PubMed] [Cross Ref]
9. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–54. doi: 10.1016/j.amjcard.2004.12.032. [PubMed] [Cross Ref]
10. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG, Duc P, Westheim A, Omland T, Knudsen CW, Storrow AB, Abraham WT, Lamba S, Wu AH, Perez A, Clopton P, Krishnaswamy P, Kazanegra R, Maisel AS. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416–22. doi: 10.1161/01.CIR.0000025242.79963.4C. [PubMed] [Cross Ref]
11. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006;47:91–7. doi: 10.1016/j.jacc.2005.08.051. [PubMed] [Cross Ref]
12. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666–75. doi: 10.1056/NEJMoa042330. [PubMed] [Cross Ref]
13. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem. 2004;50:2279–85. doi: 10.1373/clinchem.2004.035741. [PubMed] [Cross Ref]
14. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int. 2001;59:1559–66. doi: 10.1046/j.1523-1755.2001.0590041559.x. [PubMed] [Cross Ref]
15. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2007;18:321–30. doi: 10.1681/ASN.2005121299. [PubMed] [Cross Ref]
16. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int. 2007;71:548–54. doi: 10.1038/sj.ki.5002087. [PubMed] [Cross Ref]
17. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis. 2007;50:1009–19. doi: 10.1053/j.ajkd.2007.08.017. [PMC free article] [PubMed] [Cross Ref]
18. Sommerer C, Giannitsis E, Schwenger V, Zeier M. Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T. Nephron Clin Pract. 2007;107:c77–81. doi: 10.1159/000108647. [PubMed] [Cross Ref]
19. Roberts MA, Srivastava PM, Macmillan N, Hare DL, Ratnaike S, Sikaris K, Ierino FL. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin J Am Soc Nephrol. 2008;3:1057–65. doi: 10.2215/CJN.05151107. [PubMed] [Cross Ref]
20. Luchner A, Hengstenberg C, Lowel H, Riegger GAJ, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: Direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005;46:118–23. doi: 10.1161/01.HYP.0000170140.36633.8f. [PubMed] [Cross Ref]
21. deFilippi CR, Fink JC, Nass CM, Chen H, Christenson R. N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis. 2005;46:35–44. doi: 10.1053/j.ajkd.2005.04.007. [PubMed] [Cross Ref]
22. Ooi DS, House AA. Cardiac troponin T in hemodialyzed patients. Clin Chem. 1998;44:1410–6. [PubMed]
23. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102:1964–9. [PubMed]
24. Deegan PB, Lafferty ME, Blumsohn A, Henderson IS, McGregor E. Prognostic value of troponin T in hemodialysis patients is independent of comorbidity. Kidney Int. 2001;60:2399–405. doi: 10.1046/j.1523-1755.2001.00076.x. [PubMed] [Cross Ref]
25. Conway B, McLaughlin M, Sharpe P, Harty J. Use of cardiac troponin T in diagnosis and prognosis of cardiac events in patients on chronic haemodialysis. Nephrol Dial Transplant. 2005;20:2759–64. doi: 10.1093/ndt/gfi125. [PubMed] [Cross Ref]
26. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106:2941–5. doi: 10.1161/01.CIR.0000041254.30637.34. [PubMed] [Cross Ref]
27. Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, Ishikawa T, Kurokawa H, Hirano T, Kondo T, Nagamura Y, Ezaki K, Hishida H. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta. 2001;312:69–79. doi: 10.1016/S0009-8981(01)00592-7. [PubMed] [Cross Ref]
28. Abbas NA, John RI, Webb MC, Kempson ME, Potter AN, Price CP, Vickery S, Lamb EJ. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem. 2005;51:2059–66. doi: 10.1373/clinchem.2005.055665. [PubMed] [Cross Ref]
29. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002;346:2047–52. doi: 10.1056/NEJMoa013456. [PubMed] [Cross Ref]
30. David S, Kumpers P, Seidler V, Biertz F, Haller H, Fliser D. Diagnostic value of N-terminal Pro-B-Type natriuretic peptide (NT-ProBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant. 2008;23:1370–7. doi: 10.1093/ndt/gfm700. [PubMed] [Cross Ref]
31. Fagugli RM, Palumbo B, Ricciardi D, Pasini P, Santirosi P, Vecchi L, Pasticci F, Palumbo R. Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract. 2003;95:c60–c66. doi: 10.1159/000073669. [PubMed] [Cross Ref]
32. Lee SW, Song JH, Kim GA, Lim HJ, Kim MJ. Plasma brain natriuretic peptide concentration on assessment of hydration status in hemodialysis patient. Am J Kidney Dis. 2003;41:1257–66. doi: 10.1016/S0272-6386(03)00358-5. [PubMed] [Cross Ref]
33. Sheen V, Bhalla V, Tulua-Tata A, Bhalla MA, Weiss D, Chiu A, Abdeen O, Mullaney S, Maisel A. The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J. 2007;153:244. ,e1-5. [PubMed]
34. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001;12:1508–15. [PubMed]
35. Racek J, Kralova H, Trefil L, Rajdl D, Eiselt J. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract. 2006;103:c162. doi: 10.1159/000092914. [PubMed] [Cross Ref]
36. Paniagua R, Amato D, Mujais S, Vonesh E, Ramos A, Correa-Rotter R, Horl WH. Predictive value of brain natriuretic peptides in patients on peritoneal dialysis: results from the ADEMEX trial. Clin J Am Soc Nephrol. 2008;3:407–15. doi: 10.2215/CJN.03820907. [PubMed] [Cross Ref] F1000 Factor 4.8 Must Read
Evaluated by Angela Yee-Moon Wang 29 Jan 2008, Thomas Golper 16 Jul 2008
37. Gutierrez OM, Tamez H, Bhan I, Zazra J, Tonelli M, Wolf M, Januzzi JL, Chang Y, Thadhani R. N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) concentrations in hemodialysis patients: prognostic value of baseline and follow-up measurements. Clin Chem. 2008;54:1339–48. doi: 10.1373/clinchem.2007.101691. [PubMed] [Cross Ref]
38. Winkler K, Wanner C, Drechsler C, Lilienthal J, Marz W, Krane V; for the German Diabetes and Dialysis Study Investigators Change in N-terminal-pro-B-type-natriuretic peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J. 2008;29:2092–9. doi: 10.1093/eurheartj/ehn278. [PubMed] [Cross Ref]
39. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation. 2005;112:3088–96. doi: 10.1161/CIRCULATIONAHA.105.560128. [PubMed] [Cross Ref]
40. Havekes B, van Manen JG, Krediet RT, Boeschoten EW, Vandenbroucke JP, Dekker FW. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 2006;47:823–9. doi: 10.1053/j.ajkd.2006.01.019. [PubMed] [Cross Ref]
41. Wang AY, Lam CW, Wang M, Chan IH, Goggins WB, Yu CM, Lui SF, Sanderson JE. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem. 2007;53:882–9. doi: 10.1373/clinchem.2006.078378. [PubMed] [Cross Ref]
42. Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Lui SF, Sanderson JE. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int. 2006;70:444–52. [PubMed]
43. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, Bonanno G, Fatuzzo P, Rapisarda F, Seminara G, Stancanelli B, Bellanuova I, Cataliotti A, Malatino LS. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2002;40:68–75. doi: 10.1053/ajkd.2002.33914. [PubMed] [Cross Ref]
44. Iliou MC, Fumeron C, Benoit MO, Tuppin P, Courvoisier CL, Calonge VM, Moatti N, Buisson C, Jacquot C. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. Nephrol Dial Transplant. 2001;16:1452–8. doi: 10.1093/ndt/16.7.1452. [PubMed] [Cross Ref]
45. Sharma R, Gaze DC, Pellerin D, Metha R, Gregson H, Streather CP, Collinson PO, Brecker SJ. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated troponin T. Heart. 2006;92:804–9. doi: 10.1136/hrt.2005.069666. [PMC free article] [PubMed] [Cross Ref]
46. Ooi DS, Isotalo PA, Veinot JP. Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. Clin Chem. 2000;46:338–44. [PubMed]
47. deFilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, Christenson R, Uretsky B, Smiley M, Gold J, Muniz H, Badalamenti J, Herzog C, Henrich W. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA. 2003;290:353–9. doi: 10.1001/jama.290.3.353. [PubMed] [Cross Ref]
48. Jung HH, Ma KR, Han H. Elevated concentrations of cardiac troponins are associated with severe coronary artery calcification in asymptomatic haemodialysis patients. Nephrol Dial Transplant. 2004;19:3117–23. doi: 10.1093/ndt/gfh488. [PubMed] [Cross Ref]
49. Fahie-Wilson MN, Carmichael DJ, Delaney MP, Stevens PE, Hall EM, Lamb EJ. Cardiac troponin T circulates in the free, intact form in patients with kidney failure. Clin Chem. 2006;52:414–20. doi: 10.1373/clinchem.2005.062307. [PubMed] [Cross Ref]
50. deFilippi CR, Thorn EM, Aggarwal M, Joy A, Christenson RH, Duh SH, Jeudy J, Beache G. Frequency and cause of cardiac troponin T elevation in chronic hemodialysis patients from study of cardiovascular magnetic resonance. Am J Cardiol. 2007;100:885–9. doi: 10.1016/j.amjcard.2007.04.028. [PubMed] [Cross Ref]
51. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–30. doi: 10.1016/S0140-6736(00)02060-2. [PubMed] [Cross Ref]
52. Jourdain P, Jondeau G, Funck F, Gueffet P, Le HA, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733–9. doi: 10.1016/j.jacc.2006.10.081. [PubMed] [Cross Ref] F1000 Factor 3.0 Recommended
Evaluated by Lynne Warner Stevenson
53. Choi SY, Lee JE, Jang EH, Kim MO, Baek H, Ki CS, Park SW, Kim DJ, Huh WS, Oh HY, Kim YG. Association between changes in N-terminal pro-brain natriuretic peptide levels and changes in left ventricular mass index in stable hemodialysis patients. Nephron Clin Pract. 2008;110:C93–C100. doi: 10.1159/000157622. [PubMed] [Cross Ref]
54. Wayand D, Baum H, Schatzle G, Scharf J, Neumeier D. Cardiac troponin T and I in end-stage renal failure. Clin Chem. 2000;46:1345–50. [PubMed]
55. Wallace TW, Abdullah SM, Drazner MH, Das SR, Khera A, McGuire DK, Wians F, Sabatine MS, Morrow DA, de Lemos JA. Prevalence and determinants of troponin T elevation in the general population. Circulation. 2006;113:1958–65. doi: 10.1161/CIRCULATIONAHA.105.609974. [PubMed] [Cross Ref]
56. Wu AH, Jaffe AS, Apple FS, Jesse RL, Francis GL, Morrow DA, Newby LK, Ravkilde J, Tang WH, Christenson RH, Cannon CP. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. 2007;53:2086–96. doi: 10.1373/clinchem.2007.095679. [PubMed] [Cross Ref]

Articles from F1000 Medicine Reports are provided here courtesy of Faculty of 1000 Ltd